# A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors

> **NCT04452214** · PHASE1 · COMPLETED · sponsor: **Cantargia AB** · enrollment: 19 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung
- Urothelial Carcinoma
- Malignant Melanoma
- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** CAN04
- **DRUG:** Pembrolizumab
- **DRUG:** Carboplatin
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT04452214
- **Lead sponsor:** Cantargia AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-24
- **Primary completion:** 2023-06-28
- **Final completion:** 2023-06-28
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2023-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04452214

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04452214, "A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT04452214. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*